Objectives-The objectives were to assess (a) the comparative merits of commonly used disease modifying drugs in the treatment of rheumatoid arthritis (RA) and (b) the influence of age, gender, and disease duration on the outcome of treatment.
Second line (disease modifying) antirheumatic drugs are widely used in the management of active rheumatoid arthritis (RA) and information about the relative efficacy and toxicity of available drugs is needed. Such information would be valuable to rheumatologists, general practitioners, and patients. Previous comparative studies of disease modifying drugs have been criticised because of inadequate numbers resulting in insufficient power to avoid a type II error. This has led to the use of meta-analyses.' Problems which arise with such meta-analyses include variations in enrolment criteria, in parameters used to make decisions about the continuation of treatment and in possible ethnic differences in responses to treatment. For this reason a collected analysis of prospective studies from a single centre may provide greater numbers than are available from comparative studies and at the same time more comprehensive and uniform data than is achieved by meta-analysis.
Previous studies from a single centre have shown high drop out rates from these treatments in the first year,2' a finding of considerable concern to rheumatologists. If these drugs are to 'modify' RA, long term treatment is necessary, and the initial treatment period is associated with the highest drop out rates. It therefore seemed important to analyse results from a different single centre.
In addition, concern is often expressed about the influence of age, disease duration, gender, and initial disease activity on the likelihood of continuing to receive treatment with disease modifying drugs and on the response to such treatment. 4 A large cohort of patients allows analysis of demographic variables which might assist in predicting the usefulness of treatment in different patient groups.
This collected analysis thus aims to compare clinical and laboratory response to intramuscular gold, penicillamine, sulphasalazine, and auranofin and to assess the effect of age, disease duration, gender, and initial erythrocyte sedimentation rate (ESR) on Each parameter was assessed at the outset and the change between 0-3, 0-6, and 0-12 months in relation to age, disease duration, and gender was determined.
Results
There was no significant difference between the four treatment groups in demographic variables at the outset, with similar ages, disease durations, and sex ratios (table 1) . Overall, 291 (26%) of the patients took part in more than one study. Table 2 gives a summary of the reasons for discontinuation of treatment in the first 12 months. Fewer patients discontinued intramuscular gold because of a lack or loss of effect than auranofin (X2 15-5; p<0-0001). Table 3 gives the results from sequential sulphasalazine studies; no differences were observed over the period. Table 4 gives the clinical and laboratory parameters for the four drug groups (C reactive Within group analysis: improvement in all groups, for all variables 0-6 and 0-12 months. Wilcoxon <0-0001 throughout. Between groups analysis: no significant differences between groups for any variable, except higher articular index in penicillamine group at month 0 (Kruskal Wallis p<0 05). Table 5 in ESR in the three age groups was remarkably Disease duration similar. As expected, there was an excess of older The most striking difference with age was in patients in those with longer disease duration. C reactive protein, which was higher in older In addition, the group with longer disease patients at the outset of treatment and at six duration had a higher articular index at the and 12 months.
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outset. In contrast, those with early disease had a higher platelet count and ESR. Nevertheless, the changes in articular index, platelets, and ESR for the groups of patients with disease less IM gold (n = 500) than three, 4-10, and >10 years was not 70 Sulphasalazine (n = 352) significantly different except for the change in Penicillamine (n -158)
ESR and platelets at 0-3 months, which was of patients from a single centre have suggested Although patients with a longer disease duration or lower ESR were less likely to continue treatment, age and gender had little effect on drug tolerability and older patients should be offered disease modifying treatment providing there are no contraindications. The results with respect to gender are contrary to those of Wolfe and Hawley'9 who concluded from a smaller cohort that women do less well with disease modifying drugs.
Despite intensive research it is unlikely that targeted treatment will be available in the immediate future.20 Nevertheless, several new drugs are currently being studied for disease modifying effects. Such drugs should at least equal the number of patients continuing treatment with existing disease modifying drugs in the crucial early stages, or should offer significantly lower toxicity. For the optimum use of currently available disease modifying drugs an analogy with treatment for hypertension can be drawn, where the goals are directed at optimum blood pressure control to reduce long term morbidity. Currently available drugs, with the exception of hydroxychloroquine, have been shown to retard radiological progression, 2-23 and a long term follow up study from our centre has shown that it is possible to maintain patients on disease modifying drugs over 10 years.24 Improvement with this group of drugs is undoubtedly greater than with placebo. '5 25 This analysis has shown that intramuscular gold, penicillamine, and sulphasalazine perform similarly over a period of one year and that men and women of any age, and even those with long disease duration, may benefit from a disease modifying drug. 
